الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
SUMMARY
S
ystemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder associated with increased damage to vital organ systems. Type I interferon α consider the most important cytokine in the pathogenesis of SLE. Interfero α Ab have been shown to change the interferon signature and may be helpful in management SLE and control disease activity.
Our study was a case control study, conducted on 60 patients of matched age and sex attending immunology & rheumatology outpatient clinics and wards at Ain shams university hospital during the period from September 2023 to February 2024. 30 were medically free individuals and they made the control group. As regards the cases group it was divided into further 2 groups where 30 were SLE patients not in activity and the remaining 30 patients were SLE patients in activity.
Our study strongly supports that Interferon α Ab is a good positive marker for activity in SLE patients.
Markers of activity as C3, C4, Anti-dsDNA, ESR, CRP, PR/CR ratio was highly significant when compared between three studied groups. Interferon α Ab level was negatively correlated with SLEDAI SCORE and significant with disease activity being higher in active SLE than inactive SLE than control.
Our study compared level of Interferon α Ab in SLE cases and control and revealed cut off point ≥ 38.39 ng/ml to differentiate between SLE cases and control. Comparison of Interferon α Ab level between active and inactive SLE patients interestingly revealed cut off point ≥ 82.99 ng/ml to differentiate between active and inactive SLE.
In this study, certain lab parameters such as BUN, lymphocytes and ALT were associated with statistical significance in SLE patients linking the association of SLE with other chronic illnesses such as chronic kidney disease.